Express Scripts Holding Company (NASDAQ:ESRX): Up to Date Analyst Ratings

-EPS (Q4): $1.88 vs. $1.56 previous year. Currently, Express Scripts has a Zacks Rank #2 (Buy). Total debt to equity ratio of the company for most recent quarter is 1.03 while Long term debt to equity ratio for same time period is 0.96. The firm owned 256,382 shares of the company's stock after buying an additional 8,129 shares during the period. Its last month's stock price volatility remained 1.14% which for the week stands at 1.07%. Finally, Alpha Windward LLC boosted its position in Express Scripts Holding Company by 7.9% in the third quarter. Finally, Barclays PLC restated an overweight rating on shares of Express Scripts Holding Company in a research report on Friday, December 16th. The Average Volume for the stock is measured as 4.07 Million.

Express Scripts on Tuesday reported fourth-quarter earnings of $1.43 billion, for adjusted earnings per share (EPS) of $1.88 per share. VP, Sup. Chain & Specialty at Express Scripts Holding Company (ESRX) offloaded shares in a transaction closed on Tuesday January 03, 2017.

For the fourth quarter, adjusted claims, which account for monthly prescriptions filled in retail pharmacies and 90-day fills through the company's mail-order business, fell 6.4% to 354.9 million, but stayed above the company's forecast for 314 million to 329 million in adjusted claims. Over the past five trading sessions it is 1.22%; 2.61% for the month; -5.56% for the last quarter; -11.83% for the past six-months; and 4.75% for the last 12 months. Analysts predict that Express Scripts Holding Company will post $6.39 EPS for the current fiscal year. TheStreet cut Express Scripts Holding Company from a "b-" rating to a "c+" rating in a research note on Monday, February 6th. If you are accessing this article on another website, it was copied illegally and reposted in violation of US and worldwide copyright & trademark laws. The legal version of this story can be read at

Several other hedge funds and other institutional investors have also recently modified their holdings of ESRX. The company's shares performance for the last one month was 1.50% and 5.50% in the previous week. They noted that the move was a valuation call. The shares were sold at an average price of $69.41, for a total value of $77,947.43. Morgan Stanley Downgrades the company's stock to Underweight on 6/20/16 by setting a price target of $70.

At the moment 23 analysts are watching Express Scripts Holding Company (NASDAQ:ESRX), 3 rate it "Buy", 6 "Outperform", 12 "Underperform", 2 "Sell", while 0 "Hold". The 52-week range of the share price is from $64.46 - $80.02. Following the sale, the vice president now owns 12,712 shares in the company, valued at $882,339.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.54% of the company's stock. As a PBM, Express Scripts contracts with big employers, government agencies and large insurers to manage these organizations' drug benefits programs and to lower the costs.

Related News: